Zacks Research Lowers Earnings Estimates for Cosmos Health

Cosmos Health Inc. (NASDAQ:COSM) – Equities researchers at Zacks Research decreased their FY2026 earnings per share estimates for shares of Cosmos Health in a research note issued to investors on Thursday, May 21st. Zacks Research analyst B. Sorensen now anticipates that the company will post earnings per share of $0.01 for the year, down from their previous estimate of $0.08. The consensus estimate for Cosmos Health’s current full-year earnings is $0.08 per share. Zacks Research also issued estimates for Cosmos Health’s Q4 2026 earnings at $0.04 EPS.

Cosmos Health (NASDAQ:COSM) last issued its earnings results on Thursday, May 21st. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). The business had revenue of $18.40 million for the quarter, compared to analyst estimates of $17.93 million. Cosmos Health had a negative return on equity of 52.85% and a negative net margin of 30.41%.

Cosmos Health Trading Up 4.0%

Shares of COSM opened at $0.26 on Wednesday. The company has a current ratio of 1.08, a quick ratio of 0.92 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $14.29 million, a P/E ratio of -0.41 and a beta of 5.00. The stock’s fifty day simple moving average is $0.33 and its 200 day simple moving average is $0.44. Cosmos Health has a twelve month low of $0.25 and a twelve month high of $1.32.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its position in Cosmos Health by 16.7% in the first quarter. Renaissance Technologies LLC now owns 390,500 shares of the company’s stock valued at $124,000 after purchasing an additional 55,925 shares during the period. Citadel Advisors LLC raised its position in Cosmos Health by 133.1% in the third quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock valued at $250,000 after purchasing an additional 128,776 shares during the period. Finally, XTX Topco Ltd raised its position in Cosmos Health by 52.1% in the fourth quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock valued at $50,000 after purchasing an additional 34,117 shares during the period. 12.61% of the stock is owned by hedge funds and other institutional investors.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.